Ind-Swift Laboratories Limited share price
NSE: INDSWFTLAB · ISIN INE915B01019
Key numbers
- Market cap
- ₹ 3,516 Cr
- Current price
- ₹ 404.35
- 52-week high / low
- ₹ 420 / 87
- Stock P/E
- 60.3
- Book value
- ₹ 165.8
- Dividend yield
- 0.00%
- ROCE
- 3.9%
- ROE
- 3.4%
- Debt to equity
- 0.01
- Sales growth (3 yrs)
- -19.7%
- Profit growth (3 yrs)
- -3.2%
- 1-year return
- 289.2%
About Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimuscarinic, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumarate, raltegravir potassium,…
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 158 | 153 | 151 | 170 | 191 |
| Operating profit | 9 | 1 | 4 | 21 | 33 |
| Net profit | 9 | 8 | 10 | 15 | 25 |
| EPS (₹) | 1.28 | 1.00 | 1.17 | 1.81 | 2.84 |
Concall summary (2026-08-20)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- These are expected to contribute an incremental revenue of ₹200 to ₹220 crore in FY27, and represent a key milestone in scaling our contract manufacturing business with global generic majors.
- And sir, going by your guidance in the presentation, so we are targeting 20 to 25% of CAGR in the medium term.
Growth & demand
- Ezetimibe + Atorvastatin saw the sharpest growth in the portfolio with year -on-year growth of 246.97%, more than tripling to ₹80.78 crore in FY26 from ₹23.28 crore in FY25.
- Metformin, Quetiapine and Famciclovir each registered excellent growth during the year, with Quetiapine nearly doubling to ₹ 19.75 crore and Famciclovir more than doubling to ₹18.64 crore in FY26.
Margins & costs
- Operating EBITDA margin expanded sharply by 1258 bps year -on-year to 17.91% from 5.33% in Q1 FY26.
- We were saying this to lot of investors that minimum 18 to 20% EBITDA margins are there in this business and now it has been clearly depicted.
Capex & expansion
- So that ₹250 crores will be deployed in capex over a period of 2.5 years approx.
- So the plan which we have given till FY29 should be the 90% of capacity which will be used over a period of time.
Balance sheet & cash
- So reason was basically that both the companies had hi gh leverage.
- You know, the gestation period is large; there was a lot of debt on the company.
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.